Kou Qin
Investment Director at Eisai Innovation
Cambridge, Massachusetts
Overview
Work Experience
Managing Director of Investment
2023 - Current
• Corporate VC of Eisai, a leading pharma that develops drugs for Alzheimer's disease & cancer • Investing with a strategic focus on aging-related diseases: neurodegeneration, cancer and others
Principal of Investment
2021 - 2022
• Investing in breakthrough science, platforms and proven teams to address unmet medical needs • Enabling win-win partnerships among portfolio companies, Eisai and collaborating pharma/VC firms
Eisai Innovation is a strategic investment organization.
Board Observer
2024
ProTgen aims to rejuvenate the thymus and the immune system to prevent/treat cancer and neurodegenerative diseases.
Investor
2024
eGenesis is revolutionizing human organ xenotransplantation by providing CRISPR-edited, humanized pig organs.
Investor
2023
Iambic Therapeutics is the first clinical-stage company to invent physics-informed generative AI tools, drastically accelerating small-molecule drug R&D for brain tumor.
Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform.
Raised $203,000,000.00 from Illumina Ventures, Qatar Investment Authority, Alumni Ventures, Tao Capital Partners, Mubadala Capital, Coatue, Nexus Venture Partners, Abingworth, Exor Ventures and Catalio Capital Management.
Board Observer
2023
Hyku Biosciences is pioneering the next generation of high precision covalent medicine by focusing non-cysteine amino acids (H,Y,K...) of "undruggable" targets.
Investor
2023
Tune Therapeutics is the first clinical-stage company developing CRISPR-based epigenetic editing therapeutics for common diseases. https://www.genengnews.com/news/epigenetic-editing-in-non-human-primates-presented-by-tune-at-asgct/
Tune Therapeutics is an epigenetic programming platform for the treatment of disease.
Raised $40,000,000.00 from Hatteras Venture Partners, Saisei Ventures, New Enterprise Associates, Mission BioCapital and Emerson Collective.
Board Observer
2022
RiboX Therapeutics is the first clinical-stage circular RNA (circRNA) company, founded on the pioneering work of its scientific founder, Ling-Ling Chen, in the biogenesis and functions of circRNA. With its unique protein-coding and non-coding capabilities, circRNA has the potential to overcome the current limitations of mRNA therapeutics. https://scholar.google.com/citations?user=0UNkhq4AAAAJ
Board Observer
2022
Casma Therapeutics is advancing the next generation therapeutics for the Parkinson's disease based on autophagy.
Casma Therapeutics is a biotechnology company harnessing the natural cellular process of autophagy to design new medicines.
Raised $154,870,000.00 from The Column Group, Eventide Management Partners, Euclidean Capital, Ono Venture Investment, Astellas Venture Management, Third Rock Ventures, Schroders Capital, Eisai, Mirae Asset and Amgen Ventures.
Board Observer
2022
Delivering RNA and protein drugs across the blood-brain barrier (BBB) to treat neurological diseases. https://ophidion.com/
Investor
2020
Pyrotech is founded on Shao Feng's seminal work, which illuminated the mechanism of 'Pyroptosis'. This novel form of cell death controls infection by activating strong immune responses. https://scholar.google.com/citations?user=wLg0PUQAAAAJ